Abstract
The clinical efficacy of allergen-specific immunotherapy depends on tolerance induction. Treatment success is currently limited by treatment-related adverse reactions. Novel approaches mainly target improvement of tolerability in addition to optimized immunogenicity. For epicutaneous immunotherapy (EPIT), commercially available treatment extracts are applied to skin via a patch. The route exhibits excellent tolerability and good clinical efficacy. The first encouraging data on apeanut EPIT were published in 2016. Intralymphatic immunotherapy (ILIT) study results show pronounced immunogenicity and persisting clinical efficacy after only three injections of asmall amount of established extracts. New approaches of synthetic vaccine development focus on tolerance induction. These vaccines are genetically engineered with aprecisely defined profile and can be manufactured in reproducible quality. Distinct immunogenicity of the antigenic determinants contained in the preparation as well as an optimized safety profile are expected. Grass, birch, cat, and mite vaccines are currently under investigation. Which of these approaches will gain market access is unclear up to date. Results of food immunotherapy studies reveal consistently poor tolerance and limited efficacy without encouraging perspective and are not discussed further.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
